We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old (MASQUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03364959
Recruitment Status : Recruiting
First Posted : December 7, 2017
Last Update Posted : December 7, 2017
Sponsor:
Information provided by (Responsible Party):

November 6, 2017
December 7, 2017
December 7, 2017
April 13, 2017
April 2018   (Final data collection date for primary outcome measure)
Percentage (%) of corticoisteroids proportion delivered to the nose with respect to the mouth by chromatography. [ Time Frame: 12 months ]
Compare by chromatography the proportion of product administered to the nose with respect to the mouth for the administration of inhaled corticosteroids in children with asthma. Filter doses will be expressed as a percentage of the total filtered dose.
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old
Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old
The main purpose of this open randomized, ex-vivo comparative study, is to assess and to compare the inhalable dose of inhaled corticosteroid collected through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber

The use of a face mask is recommended for inhaled treatments delivered from a pressurized metered-dose inhaler and a spacer device in infants and young children with respiratory disorders such as asthma.

The nose effectively filters the air particles and it may reduce the amount of inhaled drug. Thus it is reported that the drug deposited in the lung dose is halved in older children inhaling through the nose with respect to those inhaling through the mouth.

In very young children the efficiency of nasal filtration is unknown for inhaled treatment. In infants, an in-vitro study suggests that nasal breathing allows a similar or more important drug delivery than mouth breathing, contrary to what is observed in the oldest and adults.

So it seems of great import to characterize the drug delivery in this age group comparing the nasal with the mouth breathing.

The main purpose of this open randomized, ex-vivo comparative study, is to assess and to compare the inhalable dose of inhaled corticosteroid collected through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber. 60 children, aged between 1 and 4 years old, with a medically diagnosed asthma will be recruited. Each child will inhale four puffs of both Fluticasone 125 µg/puff and Beclometasone dipropionate 100 µg/puff administered by a single observer in a standardized and randomized way. No drug will be inhaled by the children. The drugs collected on the filters between the holding chamber and patient will be analysed by high performance liquid chromatography HPLC). Filter doses will be expressed in percentage of the total dose filtered. The analysis will cover the difference between oral dose and nasal dose compared to zero. Student's test will be performed with p < 0.05.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Asthma in Children
  • Other: Corticosteroids inhalation
    Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
  • Other: Corticosteroids inhalation
    Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
  • Experimental: Flixotide
    Patients inhale first Flixotide and then Qvar
    Intervention: Other: Corticosteroids inhalation
  • Experimental: Qvar
    Patients inhale first Qvar and then Flixotide
    Intervention: Other: Corticosteroids inhalation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
December 2018
April 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged from 1 to 4 years old
  • Male or female
  • With medically diagnosed asthma
  • Patients who are used to use an inhalation chamber with a face mask
  • Patients who have not had asthmatic decompensation for at least 1 month.
  • Patients' parents having given their written consent
  • With normal clinical respiratory examination on the day of the test.

Exclusion Criteria:

  • Patients whose parents are unable to understand the purpose and conditions of the study
  • Patients whose parents are unable to give their consent
  • Patients participating in another clinical trial or exclusion period from a previous clinical trial
  • Patients presenting with a nasopharyngeal infection in the previous month
  • Child with nasal obstruction, nocturnal snoring, adenoid facies or facial malformation
  • Patient presenting with an asthmatic decompensation episode in the previous month
Sexes Eligible for Study: All
1 Year to 4 Years   (Child)
No
Contact: Jean-Christophe DUBUS, PD-PhD 491386816 ext +33 JeanChristophe.DUBUS@ap-hm.fr
Contact: Camille DELANNOY, Manager 491382747 ext +33 drci@ap-hm.fr
France
 
 
NCT03364959
2016-47
2016-A01839-42 ( Other Identifier: ANSM )
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Assistance Publique Hopitaux De Marseille
Assistance Publique Hopitaux De Marseille
Not Provided
Study Director: Jean-Olivier ARNAUD, Director Assistance Publique Hôpitaux de Marseille
Assistance Publique Hopitaux De Marseille
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP